ANI Pharmaceuticals (NASDAQ:ANIP) PT Raised to $62.00

ANI Pharmaceuticals (NASDAQ:ANIP) had its price objective lifted by equities researchers at Truist Financial from $60.00 to $62.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “hold” rating on the specialty pharmaceutical company’s stock. Truist Financial’s price objective points to a potential upside of 5.01% from the company’s previous close.

Several other brokerages have also issued reports on ANIP. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Finally, Raymond James upped their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $77.33.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $59.04 on Tuesday. The stock has a 50-day moving average of $59.50 and a 200-day moving average of $62.19. ANI Pharmaceuticals has a one year low of $48.20 and a one year high of $70.81. The stock has a market cap of $1.24 billion, a PE ratio of 36.90 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. During the same period last year, the business posted $1.06 earnings per share. The business’s revenue for the quarter was up 18.5% compared to the same quarter last year. As a group, sell-side analysts expect that ANI Pharmaceuticals will post 3.58 earnings per share for the current year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Innealta Capital LLC bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $65,000. Ridgewood Investments LLC bought a new position in ANI Pharmaceuticals in the second quarter valued at approximately $85,000. SG Americas Securities LLC acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $106,000. XTX Topco Ltd bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $207,000. Finally, O Shaughnessy Asset Management LLC acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at approximately $218,000. 76.05% of the stock is owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.